Fundraising Fox
/Companies
Sign in

ADiTx Therapeutics

OTC: ADTX

Loma Linda, US · Founded 2017 · Delaware corporation

Find your way into ADiTx Therapeutics

Sign up to see every warm intro you have to ADiTx Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ADiTx Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ADiTx Therapeutics develops therapeutic and diagnostic products focused on immune modulation and early cancer detection through its subsidiaries. The company commercializes an apoptotic DNA immunotherapy platform designed to induce immune tolerance for autoimmune diseases and organ transplant rejection, and operates a molecular diagnostics business developing mitochondrial DNA-based biomarker tests for cancer screening and other diseases.

Biotech

Founders & leadership

ADiTx Therapeutics was founded in 2017 by Shahrokh Shabahang and Amro Albanna.

SS
Shahrokh ShabahangCo-founder
AA
Amro AlbannaCo-founder

Board

LB
Leonard BaileyBoard director

Reported raises · per SEC filings

Form D private placements

$24.4M disclosed across 6 rounds · 2018–2023

▶$6MraisedJan 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rowena AlbannaExecutive Officer
  • Amro AlbannaExecutive Officer, Director
  • Shahrokh ShabahangExecutive Officer, Director
  • Corinne PankovcinExecutive Officer
  • Brian BradyDirector
  • Charles Athle NelsonDirector
  • Jeffrey RungeDirector
  • Thomas FarleyExecutive Officer
Offering amount
$6M
Amount sold
$6M
Sales commissions
$495K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian BradyDirector
  • Shahrokh ShabahangExecutive Officer, Director
  • Corinne PankovcinExecutive Officer
  • Thomas J. FarleyExecutive Officer
  • Jeffrey W. RungeDirector
  • Rowena AlbannaExecutive Officer
  • Namvar KiaieDirector
  • Amro AlbannaExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
Sales commissions
$775K
Proceeds to insiders
$436.3K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedAug 2022 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shahrokh ShabahangExecutive Officer, Director
  • Brian BradyDirector
  • Jeffrey RungeDirector
  • Thomas J. FarleyExecutive Officer
  • Rowena AlbannaExecutive Officer
  • Namvar KiaieDirector
  • Matthew ShatzkesExecutive Officer
  • Amro AlbannaExecutive Officer, Director
  • Corinne PankovcinExecutive Officer
Offering amount
$2.2M
Amount sold
$2M
Sales commissions
$70.7K
Placement agents
Network 1 Financial Securities, Inc., Crito Capital LLC
First sale
Aug 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Corinne PankovcinExecutive Officer
  • Shahrokh ShabahangExecutive Officer, Director
  • Amro AlbannaExecutive Officer, Director
  • Rowena AlbannaExecutive Officer
  • Laura E. AnthonyDirector
  • Brian BradyDirector
  • Namvar KiaieDirector
  • Jeffrey W. RungeDirector
Offering amount
$6M
Amount sold
$6M
Sales commissions
$380K
Placement agents
Dawson James Securities, Inc.
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$109.8KraisedDec 2018 · 4 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Brian BradyDirector
  • Amro AlbannaExecutive Officer, Director
  • Leonard BaileyDirector
  • Shahrokh ShabahangExecutive Officer, Director
Offering amount
$2M
Amount sold
$109.8K
Minimum investment
$4.8K
Sales commissions
$11K
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$262.5KraisedMar 2018 · 8 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Shahrokh ShabahangExecutive Officer, Director
  • Leonard BaileyDirector
  • Amro AlbannaExecutive Officer, Director
Offering amount
$2M
Amount sold
$262.5K
Minimum investment
$12.5K
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does ADiTx Therapeutics do?
ADiTx Therapeutics develops therapeutic and diagnostic products focused on immune modulation and early cancer detection through its subsidiaries. The company commercializes an apoptotic DNA immunotherapy platform designed to induce immune tolerance for autoimmune diseases and organ transplant rejection, and operates a molecular diagnostics business developing mitochondrial DNA-based biomarker tests for cancer screening and other diseases.
Who founded ADiTx Therapeutics?
ADiTx Therapeutics was founded by Shahrokh Shabahang, Amro Albanna in 2017.
How much funding has ADiTx Therapeutics raised?
ADiTx Therapeutics has disclosed $24.4M raised across 6 rounds.
Where is ADiTx Therapeutics headquartered?
ADiTx Therapeutics is headquartered in Loma Linda, US.